Windlas Biotech Limited

Equities

WINDLAS

INE0H5O01029

Pharmaceuticals

Delayed NSE India S.E. 06:27:51 2024-06-18 am EDT 5-day change 1st Jan Change
701.4 INR -3.18% Intraday chart for Windlas Biotech Limited +5.47% +63.58%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Windlas Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Windlas Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Windlas Biotech Commissions New Injectible Manufacturing Unit MT
Windlas Biotech Limited Commissions Its Injectable Facility CI
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Windlas Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Windlas Biotech Limited Approves Final Dividend for the Financial Year 2022-23 CI
Windlas Biotech Limited Proposes Final Dividend for the Financial Year 2022-23 CI
Windlas Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Windlas Biotech's Consolidated Profit Slips in Fiscal Q4 MT
Windlas Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Windlas Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Windlas Biotech Limited Recommends Dividend CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022. CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022. CI
Windlas Biotech Limited's Equity Buyback announced on November 8, 2022 has closed with 867,747 shares, representing 3.98% for INR 217.97 million. CI
Windlas Biotech's Consolidated Profit Climbs in Fiscal Q3 MT
Windlas Biotech Limited Appoints Komal Gupta as the Chief Executive Officer CI
Windlas Biotech Appoints CEO MT
Windlas Biotech Names New CEO MT
Windlas Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Tranche Update on Windlas Biotech Limited's Equity Buyback Plan announced on November 8, 2022. CI
Chart Windlas Biotech Limited
More charts
Windlas Biotech Limited is an India-base domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP). It develops and manufactures products to customers and consumers across India and some emerging markets, internationally. The Company specializes in manufacturing oral solids dosage and oral liquids dosage (OSD/OLD). It also extends to delivering specialty capabilities such as high potency, restricted chemicals, and low solubility products. Its product categories include pain management, gastro management, nutritional/food supplement, derma and hair care, respiratory management, diabetic management, cardiac management, neuro psychiatric management, tyro care, women healthcare and others.
More about the company